Pasithea Therapeutics has announced it will exhibit at the Children's Tumor Foundation 2026 Neurofibromatosis (NF) Conference, positioning the clinical-stage biotech for greater visibility among researchers, clinicians, and patient advocacy stakeholders focused on rare tumor-predisposing genetic disorders. While Pasithea operates primarily in the pharmaceutical development space, its conference presence underscores a growing convergence between drug development pipelines and the functional ingredient ecosystem targeting neurological and oncology-adjacent conditions.
Neurofibromatosis encompasses a group of genetic disorders — NF1, NF2, and schwannomatosis — that cause tumors to grow on nerve tissue. Research into supportive care for NF patients has drawn interest from the broader nutraceutical sector, particularly as functional ingredient developers targeting neuroprotection explore adjunctive applications alongside pharmaceutical protocols. Bioavailability of neuroprotective compounds and their potential role in managing inflammation associated with tumor microenvironments remains an active area of structure-function claim investigation.
For operators and formulators tracking the rare disease adjacency space, Pasithea's exhibit signals an intent to engage multidisciplinary audiences. The NF Conference convenes leading oncologists, geneticists, and patient organizations, offering a platform where preclinical and clinical data are scrutinized against rigorous double-blind, placebo-controlled standards — a bar increasingly relevant to finished formulation developers seeking to substantiate claims in neurological wellness categories.
The functional foods and nutraceutical industry has seen rising investment in ingredients with clinically validated neurological endpoints. According to category analysts, the neuro-nutrition segment continues to attract co-manufacturing interest as brands seek white-label solutions bridging cognition, neuroprotection, and mood support. Pasithea's visibility at a rare disease forum may open dialogue between pharmaceutical researchers and nutraceutical innovators working on nootropic and neuroprotective platforms, particularly as the line between drug and supplement in neurological support categories draws increasing regulatory scrutiny from FDA.
No clinical data, dosage figures, or product formulation details were disclosed in the company's announcement. Functional News will continue to monitor Pasithea's pipeline for developments relevant to ingredient suppliers, contract manufacturers, and brand owners operating in the neuro-wellness space. The 2026 NF Conference is organized by the Children's Tumor Foundation, a leading nonprofit advancing NF research and patient care globally.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.